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INTRODUCTION: Biodegradable ureteral stents 
have proven to be a useful alternative to 
conventional stents. Furthermore, they can be 
functionalized as drug eluting stents, especially for 
urothelial tumors of the upper urinary tract. In 
these cases, the conventional method of drug 
administration is via drug instillation. This has 
several drawbacks, such as high concentration 
dosage, increased side effects, short residence time 
and low bioavailability [1]. To avoid these 
problems, biodegradable ureteral stents 
impregnated by supercritical fluid CO2 (SCF) with 
four different anti-cancer drugs were produced.  
METHODS: Biodegradable ureteral stents were 
produced according previous work [2]. Four types 
of drug-eluting biodegradable stents based on 
natural polymers were prepared. The stents were 
impregnated by SCF (40°C, 100 bar, 90 min), with 
paclitaxel, epirubicin, doxorubicin and 
gemcitabine. The release kinetics of the 
impregnated drugs from the anti-cancer drug-
eluting stents was evaluated in artificial urine 
solution (AUS) for 9 days. The anti-tumoral effect 
of the developed stents in transitional cell 
carcinoma (T24) and HUVEC primary cells, used 
as control, was evaluated. 
RESULTS: The in vitro release study in AUS 
showed a sustainable release in the first 72h for the 
four drugs impregnated, after this time a plateau 
was achieved and finally the stent degraded after 9 
days. To determine the sensitivities to each drug 
(IC50), a T24 cancer cell line was exposed to 
graded concentrations (0.01 to 2000 ng/ml) of the 
four drugs for both 4h and 72h. Additionally, 
toxicity as a result of both direct and indirect 
contact of the cell lines with the different material 
conditions of biodegradable stent were studied. 
The four anti-cancer drugs studied showed a 
concentration-dependent inhibitory effect on the 
T24 and (control) HUVEC cell lines with IC50’s 
for paclitaxel of 7.30 ng and 501.50 ng, 
respectively. The T24 cancer cell line was shown 
to be more sensitive than the control HUVEC cell 
line for all the anti-cancer drugs tested. 
 
Fig. 1: Release profile of the different stents 
impregnated with paclitaxel. Comparison with 
IC50 concentration for T24 and HUVEC cells. 
 
DISCUSSION & CONCLUSIONS: The direct 
and indirect contact of the anti-cancer 
biodegradable stents with the T24 and HUVEC 
cells confirm the anti-cancer effect of the stents 
impregnated with the four anti-cancer drugs, 
reducing approximately 75% of the viability of the 
T24 cell line after 72h and no negative effect in the 
HUVEC cells for the total drug release from stents. 
This study has thus shown the efficacy of the anti-
cancer drug eluting biodegradable stents in vitro 
for the T24 cell line, with no toxicity observed in 
non-cancerous HUVEC cells. 
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